MECP2 and Rett syndrome: We designed a nuclease-free HR-based genome editing strategy to correct pathogenic Rett syndrome-associated MECP2 mutations located in Exons 3 and 4 using the AAVHSC editing platform (Smith et al., 2018; Chen et al., 2020; Prout et al., 2023).